GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Astria Therapeutics Inc (NAS:ATXS) » Definitions » E10

ATXS (Astria Therapeutics) E10 : $-124.39 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Astria Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Astria Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-124.39 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-12), Astria Therapeutics's current stock price is $10.50. Astria Therapeutics's E10 for the quarter that ended in Sep. 2024 was $-124.39. Astria Therapeutics's Shiller PE Ratio of today is .


Astria Therapeutics E10 Historical Data

The historical data trend for Astria Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astria Therapeutics E10 Chart

Astria Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -135.07

Astria Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -138.90 -135.07 -133.47 -129.41 -124.39

Competitive Comparison of Astria Therapeutics's E10

For the Biotechnology subindustry, Astria Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astria Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Astria Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Astria Therapeutics's Shiller PE Ratio falls into.



Astria Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astria Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.42/133.0289*133.0289
=-0.420

Current CPI (Sep. 2024) = 133.0289.

Astria Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -41.725 99.070 -56.028
201503 -28.163 99.621 -37.607
201506 -484.199 100.684 -639.749
201509 -33.000 100.392 -43.728
201512 -37.800 99.792 -50.390
201603 -36.600 100.470 -48.461
201606 -36.600 101.688 -47.880
201609 -32.400 101.861 -42.314
201612 -27.000 101.863 -35.261
201703 -24.600 102.862 -31.815
201706 -19.200 103.349 -24.714
201709 -18.600 104.136 -23.761
201712 -13.920 104.011 -17.804
201803 -17.280 105.290 -21.833
201806 -11.880 106.317 -14.865
201809 -4.800 106.507 -5.995
201812 -3.480 105.998 -4.367
201903 -3.720 107.251 -4.614
201906 -3.720 108.070 -4.579
201909 -3.360 108.329 -4.126
201912 -3.300 108.420 -4.049
202003 -3.000 108.902 -3.665
202006 -3.180 108.767 -3.889
202009 -3.360 109.815 -4.070
202012 -2.640 109.897 -3.196
202103 -45.600 111.754 -54.281
202106 -5.330 114.631 -6.185
202109 -0.610 115.734 -0.701
202112 3.230 117.630 3.653
202203 -1.180 121.301 -1.294
202206 -0.860 125.017 -0.915
202209 -0.870 125.227 -0.924
202212 -0.720 125.222 -0.765
202303 -0.400 127.348 -0.418
202306 -0.450 128.729 -0.465
202309 -0.630 129.860 -0.645
202312 -0.940 129.419 -0.966
202403 -0.380 131.776 -0.384
202406 -0.430 132.554 -0.432
202409 -0.420 133.029 -0.420

Add all the adjusted EPS together and divide 10 will get our e10.


Astria Therapeutics  (NAS:ATXS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Astria Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Astria Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Astria Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
75 State Street, Suite 1400, Boston, MA, USA, 02109
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Executives
Christopher Morabito officer: Chief Medical Officer C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Andrea Matthews officer: Chief Business Officer C/O ASTRIA THERAPEUTICS, INC., 75 STATE STREET, SUITE 1400, BOSTON MA 02109
Andrew Komjathy officer: Chief Commercial Officer CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B14202, CAMBRIDGE MA 02139
Andrew John Nichols officer: Chief Scientific Officer C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG 1400E, CAMBRIDGE MA 02139
Perceptive Xontogeny Venture Fund, Lp director, 10 percent owner C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Xontogeny, Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director, 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joanne T. Beck director C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ, BLD. 1400E, SUITE B14202, CAMBRIDGE MA 02139
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Hugh M Cole director C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Benjamin Harshbarger officer: Secretary and General Counsel ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142